October 15, 2019 09:50 AM EDTUpdated 10:38 AM
News Briefing

Check­mate Phar­ma­ceu­ti­cals brings two new ex­ecs on board; Take­da sheds 30 drugs, gains $200M in Aci­no deal

Kathy Wong

Editor

→ Amid a $22 mil­lion fi­nanc­ing round led by Decheng Cap­i­tal last year, Check­mate Phar­ma­ceu­ti­cals CEO Art Krieg an­nounced that he was turn­ing in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times